Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing
David Moatazedi, Director, President & CEO, on March 19, 2024, sold 96,566 shares in Evolus (EOLS) for $1,344,604. Following the Form 4 filing with the SEC, Moatazedi has control over a total of 695,8
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBiolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. As per the press release, Q4 earnings ca
Evolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth Investors
GLP-1 Drugs Are About To Unleash a Gold Rush for Cosmetic Procedures, Benefiting Evolus (EOLS), Inmode (INMD), and AbbVie (ABBV) Shares
Survey Finds GLP-1 Users More Inclined to Get Aesthetic Procedures
Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS)
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its Annual Results
Last week, you might have seen that Evolus, Inc. (NASDAQ:EOLS) released its full-year result to the market. The early response was not positive, with shares down 4.5% to US$14.07 in the past week.
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Evolus, Inc. (NASDAQ:EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on
Evolus (EOLS) Receives a Buy From Barclays
Evolus Poised for Growth: Buy Rating Affirmed With $25 Price Target Amid Profitability Forecast and Competitive Market Positioning
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report
Evolus Full Year 2023 Earnings: In Line With Expectations
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 11,355
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% recently. Amylyx Pharmaceutica
Evolus Price Target Maintained With a $22.00/Share by Needham
Evolus Price Target Maintained With a $22.00/Share by Needham
Evolus Is Maintained at Buy by Mizuho
Evolus Is Maintained at Buy by Mizuho
Express News | Mizuho Maintains Buy on Evolus, Raises Price Target to $23
No Data